We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Alcon Inc | NYSE:ALC | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 82.01 | 0 | 01:00:00 |
By David Sachs
Shares in Alcon rose Wednesday after the Swiss company reported positive results for a dry-eye disease treatment undergoing two trials.
At 0834 GMT, Swiss shares of Alcon were up 4.8% at CHF69.46. They had risen as high as CHF70.20
The Swiss eye-care company said late Tuesday that it achieved its primary goals with statistical significance for AR-15512, a candidate to treat dry-eye disease. It plans to file a new drug application with the U.S. Food and Drug Administration in mid-2024, it said.
The drug works demonstrably faster than competitors Restasis and Xiidra, positioning it to grab a significant piece of the U.S. market, Citi analysts said in a research note on Wednesday. Analysts estimated an earnings-per-share upside of around 3% for every $100 million in sales by 2026. The dry-eye treatment market in the U.S., where Alcon is also listed, is worth between $1.5 billion and $2 billion, Citi said.
Alcon also met secondary goals, including rapid and sustained tear production, it said.
Write to David Sachs at david.sachs@wsj.com
(END) Dow Jones Newswires
January 10, 2024 03:57 ET (08:57 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year Alcon Chart |
1 Month Alcon Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions